05403nam 2200649 450 991013147200332120210603001424.01-118-84619-21-118-84621-41-118-84620-6(CKB)3710000000476377(EBL)4039212(SSID)ssj0001553100(PQKBManifestationID)16171379(PQKBTitleCode)TC0001553100(PQKBWorkID)14813119(PQKB)11358207(PQKBManifestationID)16176019(PQKB)21181626(MiAaPQ)EBC4039212(DLC) 2015012590(Au-PeEL)EBL4039212(CaPaEBR)ebr11112843(CaONFJC)MIL831286(OCoLC)905802006(PPN)194583945(EXLCZ)99371000000047637720151104h20152015 uy 0engur|n|---|||||txtccrStem cells in regenerative medicine science, regulation and business strategies /edited by Alain A. Vertes [and three others] ; contributors, Timothy E. Allsopp [and sixty others]Chichester, England :Wiley Blackwell,2015.©20151 online resource (1202 p.)Description based upon print version of record.1-119-97139-X Includes bibliographical references at the end of each chapters and index.Therapeutic stem cells answer a strategic breakthrough need of healthcare / Alain Vertes -- Ethical considerations on the research and business of stem cells / Ljiljana Minwalla -- Projected growth of the worldwide stem cell market / Ed Field -- Cell therapy manufacturing: identifying and meeting demand / Jessica Carmen, David A. Brindley, Natasha L. Davie and David Smith -- The history of stem cell transplantation / Hilliard M. Lazarus and Stan Gerson -- Regulatory and intellectual property considerations for therapeutic human stem cell-based regenerative medicine product development: a U.S. perspective / Michael Mendicino and Darin Weber -- The regulation of stem cells in the UK and EU / Alex Denoon, Julian Hitchcock and James Lawford Davies -- The business of stem cell research tools / Erik Miljan -- Stem cell-derived cardiomyocytes and hepatocytes as tools for drug development and screening applications / Kate Camerona, Howard Marriage, David Haya and Claire Medine -- Stem cell tools for compound development / Tom Novak -- Stem cell origin of cancer: prospects for functional therapeutics and regenerative medicine / Vinagolu K. Rajasekhar -- The market of stem cell medicines for domestic and high value animals / Bob J. Harmann -- Stem cells veterinary medicines: a conceptual approach / John Peroni and Lindsey Boone -- Stem cells in veterinary medicines: a practical approach / Bob J. Harmann -- Stem cell veterinary medicines as success signals towards human stem cell therapeutics / Alain Vertes -- Animal models in regenerative medicine / Andrew N. Bubak, John D. Elsworth and John R. Sladek, Jr. -- Stem cell characterization: a guide to stem cell types, technologies, and future applications / Justin Lo Re, Rezma Shrestha and Leonard Sciorra -- Stem cell value chains / Judy Muller-Cohn, Paul Diaz and Rolf Muller -- Stem cell culture processes / Ravali Raju, Shikha Sharma and Wei-Shou Hu -- Indication transformation maps and the challenge of live cells delivery / Bob Deans and Lee Babiss -- Delivery and targeting of therapeutic cells / Paul Lin, Arnold I. Caplan and Erkki Ruoshlati -- Hematopoietic stem cells / Steve Wolpe and Lynnet Koh -- MSCs: the new medicince / Arnold Caplan -- Innovation and commercialization of induced pluripotent stem cells / Shintaro Sengoku -- Embryonic stem cells / Rachel Eiges, Benjamin E. Reubinoff and Charles Irving -- Allogeneic versus autologous stem cell transplantation in regenerative medicine / Kathy Trzaska-Accurso and Pranela Rameshwar -- Clinical immunological barriers to regenerative medicine: do they matter? / Cristina Trento and Francesco Dazzi -- Challenges in the clinical development of stem cells / John Caulfield -- Pricing and reimbursement of regenerative medicines / Nathan Dowden -- The role of patient advocacy in the clinical translation of regenerative medicine / Bernard Siegel and Alan Jakimo -- Financing strategies for regenerative medicine start-ups / Carol Julie Walton, Lee Buckler and Gregory A. Bonfiglio -- Strategic alliances, mergers and acquisitions in regenerative medicine / Nafees N. Malik, Timothy E. Allsopp and Devyn M. Smith -- History of monoclonal antibodies and lessons for the development of stem cell therapeutics / Alain Vertes and Nathan Dowden -- Deployment of stem cell technologies in industry and healthcare/ Alain Vertes.Stem cellsRegenerative medicineStem cells.Regenerative medicine.616.02/774‪Rajasekhar ‪Vinagolu KMSKCC.879114Vertes Alain A.Allsopp Timothy E.Memorial Sloan Kettering Cancer Center (MSKCC).MiAaPQMiAaPQMiAaPQBOOK9910131472003321Stem cells in regenerative medicine2033563UNINA